Acute Myeloid Leukemia (AML) is an aggressive cancer with poor overall survival due to frequent relapse. FMS-like tyrosine kinase (FLT3) is the most commonly mutated gene [...]

Identification of druggable mutations in Acute Myeloid Leukemia (AML), such as FLT3-ITD, has led to the development of targeted therapies capable of out-performing cytoto [...]

November 2013 issue of the Scribe. Contents include clinical trials for acute myeloid leukemia treatment, care for senior patients, liability insurance, management of use [...]

Acute myeloid leukemia (AML) is the most common leukemia in adults and is primarily diagnosed in older patients. The combination of the BCL2 inhibitor, venetoclax, with a [...]

Despite decades of conventional chemotherapy, the prognosis for patients with acute myeloid leukemia (AML) remains dismal, with 75% of patients succumbing to their diseas [...]

Gene transcription is fundamental in establishing and maintaining cell identity and function. All normal cells are encoded with the same DNA, so transcription is essentia [...]

This thesis is composed of two studies that utilizes different statistical methods to answer cancer research questions. The first study uses supervised and unsupervised s [...]

Abnormal splicing events can promote drug resistance in a variety of cancer types, however, the full extent of genome-wide splicing in therapy-resistant AML is not fully [...]

Contributing to proteomic diversity, alternative splicing of pre-mRNA is widespread in the human transcriptome and can greatly influence regulation of both normal and dis [...]

Leukemias comprise a family of hematologic malignancies characterized by the over-proliferation of myeloid precursor cells. Leukemia development depends on multiple facto [...]